2011 Leadership in Pharmaceuticals & Biotechnology
2011 Leadership in Pharmaceuticals & Biotechnology
June 16, 2011 - New York, NY
JOIN LIKE-MINDED PROFESSIONALS IN YOUR FIELD FOR A FULL DAY OF LEARNING. EXPLORE CUTTING EDGE CONTENT AND EXPAND YOUR NETWORK WITH THE BEST AND BRIGHTEST EXECUTIVES IN THE REGION!
As the pharmaceutical and biotech industries face pending healthcare and biologics legislation, the future of the industry remains in flux. Many companies have generics coming off patent necessitating discussion on new investments, pipeline issues and increased research & development.
These are amongst the topics that will be addressed on June 16th, when Argyle Executive Forum will host its Leadership in Pharmaceuticals and Biotechnology meeting, taking place in Manhattan.
This event will feature insights from top
Otsuka America Pharmaceutical, Inc. View Bio »
A seasoned and highly successful healthcare executive with over 25 years experience in the pharmaceutical industry, Mark Altmeyer joined Otsuka America Pharmaceutical, Inc. (OAPI) in January 2009 as President and Chief Executive Officer.
Mr. Altmeyer earned his well-deserved reputation as a drug commercialization strategist and leader prior to coming to Otsuka. Developing an impressive background in pharmaceutical sales and marketing, he spent over twenty years with Bristol-Myers Squibb Co. rising from Sales Representative to Senior Vice President, Global Commercialization. During those years, he also held positions of increasing importance including product manager, director, senior director, vice president and senior vice president, delivering on premier brands including Pravachol, Glucophage, and ABILIFY.
Extending his successes beyond the U.S. market, Mr. Altmeyer worked internationally as the general manager of BMSs operations in Turkey. This led to his appointment as Senior Vice President, Global Commercialization. In that position, he was responsible for the global marketing of all neuroscience and oncology assets – the therapeutic areas on which Otsuka is focusing, and which will help us drive Otsuka’s future, rapid growth.
Prior to joining BMS in 1992, Mr. Altmeyer devoted his efforts to marketing and development for Cetus Corporation, both as a product manager in oncology and a business development manager. He started his career with Bristol Labs, a division of Bristol-Myers, as a marketing associate and group product analyst.
Mr. Altmeyer earned his Bachelors of Arts Degree from Middlebury College in Vermont, and his Masters in Business Administration from Harvard Graduate School of Business. Active in the healthcare arena as well as his own community, he is on the Board of Directors for both Contact of Mercer County and the Trinity Counseling Service. In addition he also serves as a Middlebury College Alumni Recruiter. He, his wife Sharon, and their three children reside in Princeton, NJ.
IntraLinks View Bio »
Linda Bowers is Vice President of Life Sciences Product Marketing at IntraLinks. Linda is responsible for building on IntraLinks’ position as the leading software-as-a-service solution for critical information exchange in the life sciences industry, working closely with industry leaders to understand market trends, market problems and industry drivers to guide product strategy and direction at IntraLinks.
Linda’s background includes 20 years of experience in the healthcare, life sciences and technology industry Prior to IntraLinks, she was senior director, global life sciences industry solution management at SAP Labs, LLC responsible for the growth of the life sciences industry, both organically and through strategic transactions. Prior to SAP, Linda joined a start up biotechnology company. As it tripled growth, she developed a comprehensive cGMP compliant materials management, and actively participated in the IPO efforts. Ms. Bowers was a key core team member to build a new cGMP facility and subsequently, launched CarticelSM shortly after the company was acquired by Genzyme.
Linda holds an M.B.A. from Simmons School of Management, with highest honors and a B.A. in molecular biology magna cum laude from Wellesley College.
Akorn, Inc. View Bio »
Sean Brynjelsen is Vice President of New Business Development at Akorn Inc. a a generic pharmaceutical company, engaged in the development, manufacture, and marketing of multi-source pharmaceutical products in the areas of ophthalmology and hospital injectables. An accomplished veteran with over 17 years experience in both branded and generic pharmaceuticals his background includes pharmaceutical development, due diligence, project management and strategic planning. Prior to joining Akorn, Mr. Brynjelsen held progressively responsible positions within R & D and Program Management at Hospira International and Baxter Healthcare Corporation. Mr. Brynjelsen holds a BS Biochemistry and MS Chemistry from the University of Illinois and an MBA from the University of Notre Dame
A.T. Kearney View Bio »
Carol Cruickshank is a Partner with A.T. Kearney’s Pharmaceutical and Healthcare practice. She has over fifteen years of industry and consulting experience across the healthcare value chain serving pharmaceutical and biotech clients, health insurers and retail pharmacies. Carol supports clients on a range of strategic and operational issues including go to market strategy, operational efficiency and organizational effectiveness. Most recently, Carol co-led the firm’s research in biopharmaceutical cost structure and improvement. Carol has a B.A. from Queen’s University in Canada and a Masters of Business Administration from the Ivey Business School at the University of Western Ontario.
A.T. Kearney is a top tier management consulting firm focused on delivering high quality, tangible results to its clients. Established in 1926, A.T. Kearney was founded to provide management advice concerning issues on the CEO’s agenda. Today, A.T. Kearney serves the largest global clients in all major industries with offices located in major business centers in xx countries.
Bingham McCutchen View Bio »
Matt Cushing has a general corporate and securities practice with a concentration in representing both financial and strategic acquirors and sellers in M&A transactions. He has represented public, private and emerging growth companies, as well as investment banks and private equity and venture capital firms, in a wide range of corporate matters. His current experience includes venture financings, PIPEs and public offerings of equity and debt securities, the acquisition and sale of organizations. operating assets and intellectual property, and joint ventures and securities law compliance.
Matt also represents 501(c)(3) tax-exempt organizations on a pro-bono basis, is active in the firm’s attorney development and mentoring efforts, and is a member of the firm’s hiring committee.
US CEEDD, GSK View Bio »
Dr. Donabedian is Vice President, Global New Deal Strategy and Development and is a member of the ceedd leadership team. In this role, he is accountable for setting the ceedd new deal portfolio strategy and composition and working closely with GSK worldwide business development to establish new alliances. Prior to this position, Dr. Donabedian was the Vice President of Strategic Alliances in GSK's Centre of Excellence for External Drug Discovery (ceedd) where he was responsible for identifying and evaluating new business opportunities for the U.S. ceedd and supporting the current network of external alliances.
Prior to joining the ceedd, Dr. Donabedian built a successful consultancy practice providing business development services to both public and private biotechnology companies. He has sourced and closed several agreements with biopharmaceutical companies and academic institutions.
Dr. Donabedian's previous senior level positions include CEO, COO and VP of Business Development for Tutorzilla, BioChemics, and Surface Logix. Dr. Donabedian also worked as a Sr. Manager in Accenture's Strategic Services Consulting Group serving both in the U.S. and internationally, with assignments focusing on R&D post-merger integration, business unit strategy, and resource planning. Prior to Accenture, Dr. Donabedian held senior level positions at Sentry® Products, a Union Carbide life science venture (now Dow Chemical), where he headed a product development team specializing in developing and patenting a broad range of technologies to the life sciences industries. Dr. Donabedian began his research career as a scientist with SciMed Life Systems, a division of Boston Scientific. Dr. Donabedian is an inventor/co-inventor on several patents and has published several papers in peer-reviewed journals in the field of polymer science.
Since 2006, Dr. Donabedian has served as a member of University of Massachusetts Lowell Plastics Advisory Committee. He is also as an Alumni Network Advisor for the University of North Carolina Business School. He received an A.B. from St. Anselm College, a Ph.D. in polymer chemistry from the University of Massachusetts Lowell and an M.B.A. from the University of North Carolina Chapel Hill where he was a Deloitte Case Cup Challenge Winner.
PwC View Bio »
Dimitri is the leader of PricewaterhouseCoopers’ Transaction Services Life Sciences sector. Dimitri advises corporate clients on the structuring of complex merger & acquisition transactions, alliances, partnerships and joint ventures, as well as minority and early-stage investments to successfully integrate and address accounting, financial reporting, corporate finance, and valuation challenges. In addition, he is a leading advisor within the Firm to clients on valuation principles, methodologies and critical assumptions employed in various business enterprise, intangible asset and security valuation exercises across the spectrum of companies in the pharmaceutical and life science sectors.
Dimitri is a leader in the Firm’s thought leadership efforts on the financial reporting rules surrounding valuation and has formulated the key implications and strategic insights for deal principals and various industry participants to consider. In addition, he has worked closely with the Firm’s National Office and valuation professionals to understand, interpret and shape the new rules, both from a financial reporting as well as a valuation perspective.
Dimitri, a CPA and a CFA, received his MBA in finance and economics from the University of Chicago and his BS in accounting from Bucknell University.
Former Vice President, Corporate Strategy, Celgene View Bio »
Chris joined AVI as President and Chief Executive Officer on January 1, 2011. He has served as a director of the Company since June 2010. Previously he was Vice President of Corporate Strategy for Celgene Corporation from July 2007. From November 2005 to June 2007, Chris served as an independent consultant to early stage biopharmaceutical companies. From 1997 to 1998 and from 1999 to November 2005, he worked at Gilead Sciences, Inc., where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. Chris also held various commercial roles at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997. He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994. Chris received his BS in marketing from the University of Maryland.
Kaye Scholer View Bio »
Adam Golden is a Partner in and Co-Chair of the Corporate & Finance Department of Kaye Scholer LLP. A leader in Kaye Scholer’s esteemed Life Sciences practice, Mr. Golden heads the firm’s Life Sciences Transactional group.
Mr. Golden's practice focuses on structuring and negotiating complex business transactions, including mergers and acquisitions, joint ventures, and the full range of licensing and collaboration transactions common to the life sciences sector. He has also represented both issuers and investors in public and private securities offerings, including venture capital, private equity and PIPE financings.
Mr. Golden has substantial experience representing clients for whom intellectual property is a key asset. As a lawyer with a background in science, he brings an in-depth understanding of the technology involved in transactions for the benefit of his clients. His clients include companies in the pharmaceutical and biotechnology, chemicals, information technology, healthcare services, medical devices, defense, consumer products, finance and alternative asset management industries. Mr. Golden’s practice is international in scope, and his clients range in size from multibillion-dollar global businesses to emerging-stage companies.
Chambers USA: America’s Leading Lawyers for Business (2009) and (2010) recognized Mr. Golden and rated Kaye Scholer’s multidisciplinary Life Sciences practice as being among the strongest in the nation, winning praise for “comprehensive service” with a “results-oriented approach and deep understanding of the market.”
Merck & Co., Inc. View Bio »
Starting in 2009, Keith Gottesdiener, M.D., was Vice President and Late Stage Therapeutic Group Leader, and in that role led the late stage clinical development efforts of Merck Research Laboratories. After the merger, he was co-lead of late development, with responsibility for four of the main therapeutic areas including infectious disease, vaccines, cardiovascular and diabetes/obesity. Starting in March 2011, he is Vice President, and Special Assistant to the Head of Development.
Dr. Gottesdiener joined Merck Research Labs as an associate director in early clinical development in 1995. In that role he helped transition compounds from the bench to the bedside and through to proof of concept. During the next 10 years at Merck, he held positions of increasing responsibility, eventually leading the early clinical development/clinical pharmacology department at Merck from 2001 through early 2006. From 2006-2008, he was leader of the Clinical Infectious Diseases and Vaccines area, overseeing the development of Merck's infectious diseases and vaccine products from early clinical studies, through late clinical development, registration, and life cycle management.
Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his residency in internal medicine at the Brigham and Women's Hospital of Harvard Medical School. He also completed an infectious diseases fellowship at the combined Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital program. In 1986, he joined the faculty as an assistant professor at Columbia University, and before leaving for MRL, Dr. Gottesdiener was appointed Associate Clinical Professor of Medicine at Columbia University.
Novartis Pharmaceuticals Corporation View Bio »
Milton Grannatt is Vice President and Head, Search & Evaluation and Negotiations for Respiratory in Global Business Development and Licensing at Novartis. Prior to Novartis, he held senior positions at Sterling Winthrop and Lex service, an acquisitive, diversified UK-based company. Dr Grannatt has an extensive deal sheet.
Dr Grannatt received his undergraduate degree and PhD in Economics from Lehigh University.
Kaye Scholer LLP View Bio »
William Hoffman is a partner in the Washington office of Kaye Scholer, LLP. He has spent the last 15 years representing life sciences companies in product liability and governmental litigation, criminal investigations, risk mitigation planning and regulatory compliance. He is an experienced trial lawyer who has tried numerous cases in state and federal courts and is a nationally-recognized appellate advocate who has argued on behalf of public and private clients throughout the country, including matters in which he was specially appointed by federal appellate courts.
Prior to entering private practice, William served for four years as an Assistant United States Attorney for the Southern District of New York and as a law clerk for the Honorable Judge James L. Buckley, a judge on the United States Court of Appeals for the District of Columbia Circuit.
Perrigo Company View Bio »
Mr. Sharon Kochan is Executive Vice President and GM of the Generic Prescription (Rx) Pharmaceuticals Segment for Perrigo Company, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API) with annual sales in excess of $2.5 Billion.
Sharon started his career in pharmaceuticals with Clay-Park Labs in 1994 as a project manager, and grew through the ranks, and by way of acquisitions, to serve as SVP of Business Development and Strategy for Perrigo Company in March 2005, further to the acquisition of Clay-Park Labs/Agis by Perrigo in March 2005.
In March 2007, Sharon Kochan was promoted to an EVP role with responsibility to lead the Rx generic segment of Perrigo, which had just over $100M in annual sales at that time. With impressive growth trajectory, driven both by fruition of an organic pipeline as well as select product acquisitions, the Perrigo Rx segment annual sales run rate exceed $300M by 2010 H2 with high operating margins. After the recently announced acquisition of Paddock Labs from January 2011, expected to close during Q2 of FY2011, the Perrigo Rx generic segment is forecasted to exceed $500M in annual sales with operating margins well above the industry averages.
Sharon Kochan holds a BSc. degree in Industrial Engineering, cum laude, from Tel-Aviv University, and MSc. degree in Operations Research from Columbia University in NYC.
RR Donnelley View Bio »
Jeff Levy is Director of Business Development at RR Donnelley, a global provider of integrated communications. After spending 20 years in capital market sales providing financial print and virtual data room services to the New York region and Latin America, Jeff now devotes his efforts on leveraging RR Donnelley’s global network and new technology to develop solutions for the Life Science sector. His areas of focus include data rooms for licensing and partnership agreements, patient recruitment and retention services, management of clinical study documents, translation, and creating novel approaches for advisory boards and the medical community to share vital information.
Jeff is currently a platinum committee member of BioNJ. He has a B.S. in Marketing from the University of Maryland and currently resides in Livingston, New Jersey with his wife and two daughters.
PwC View Bio »
Michael has more than fourteen years of experience assisting organizations achieve transformational change and improving business performance through operations improvement. His area of expertise is in leading the development and deployment of new strategies, processes, and technology. He has global experience in the consulting, pharmaceutical planning and financial services industries.
Currently, Michael is the Global Pharmaceutical and Life Sciences R&D Advisory Services Leader for PricewaterhouseCoopers’ and is based in New York City. He is primarily focused on R&D operations and business planning, project management, and organization development. His areas of specialization include: senior-management decision support, demand management, portfolio visualization, operational planning, organization design, and process engineering. He has developed strategic and tactical programs to help organizations define and implement desired changes, as well as foster the leadership skills needed for the new environment.
Prior to joining PwC, he was the founder and president of Intendere Consulting, a specialized consultancy established to develop and execute practical R&D services and strategies for pharmaceutical and biotechnology companies. While at Intendere, Michael led projects for both large- and medium-size pharmaceutical organizations, helping them achieve greater efficiency through the development of operations planning organizations, systems, processes and tools. Earlier in his career he was a management consultant in the Life Science Strategy practice at Deloitte Consulting based in New York City.
Michael holds a B.S. in Industrial / Organizational Psychology and a B.S. in Biology from Brooklyn College and a M.A. in Organization Psychology from Columbia University. He is a visiting professor for several universities and teaches Organization Behavior and Leadership. Michael is an advisory board member within The Pharmaceutical Community of Practice with PMI and an implementation taskforce member for FDA Modernization committee.
Pfizer Inc. View Bio »
Polly Murphy leads the Worldwide Business Development team that supports Pfizer’s R&D organization. This team is a global group of professionals focused on licensing and alliance management. She also serves on the Board of Directors for The Pfizer Incubator.
Prior to Pfizer, she was Sr. Vice President, Business and Scientific Services at The Scripps Research Institute. In this role she led organization-wide business development and technology commercialization functions and was responsible for operation of the scientific support functions at the La Jolla campus. Before joining Scripps, Polly was VP, Office of Technology Management at the Salk Institute where she was responsible for protecting and commercializing Salk technologies. Previously she was in Business Development at Aurora Biosciences after holding several positions for Dupont Pharmaceuticals the last being vice president for portfolio planning and valuation. Of note, she headed the U.S. marketing team that launched DuPont Pharma's HIV drug Sustiva. Prior to Dupont, she worked for Nabi Biopharmaceuticals where she was director of business development. She began her career at Hoffman-LaRoche as a post-doc in the experimental pathology group followed by positions in sales and marketing.
Polly holds Doctor of Veterinary Medicine and Ph.D. in Veterinary Pathology degrees from Iowa State University and an M.B.A. from Nova Southeastern University. She lives in San Diego with her husband and two sons, ages 8 and 9. In her spare time she enjoys surfing and spending time with her family.
Infinity Pharmaceuticals, Inc. View Bio »
Adelene Q. Perkins has served as Infinity’s president and chief executive officer since 2009. Ms. Perkins first joined Infinity as chief business officer in 2002 and then served as president and chief business officer of Infinity from 2008-2009. Since joining Infinity, she has played an integral role in developing Infinity's business strategy, leading the company in its transition from a platform to a product-based organization. She has also been the principal figure in structuring, executing and managing all of Infinity's innovative strategic relationships, including its global alliance with Mundipharma International Corporation Ltd. and Purdue Pharmaceutical Products L.P.
Ms. Perkins has more than 25 years of international business and corporate strategy experience in the biopharmaceutical industry, focused on licensing and business development, strategic finance, product life cycle management, and leading high-caliber, cross-functional teams. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Wyeth, where she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University directed at discovering and developing members of the TGF-b superfamily. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives and was responsible for numerous business development transactions, including both in- and out-licensing technologies and products. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.
Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Board of Project Hope and the Villanova University College of Engineering Advisory Board.
Boehringer Ingelheim USA Corporation View Bio »
Marla Persky is Senior Vice President, General Counsel and Corporate Secretary for Boehringer Ingelheim USA. She oversees a department of over 70 individuals. She is a member of Boehringer’s executive management team where she participates in strategy, portfolio oversight, and business management operations.
Prior to joining Boehringer Ingelheim, Ms. Persky spent 19 years at Baxter International Inc. where she held numerous business and legal positions, the most recent of which was Acting General Counsel and Corporate Secretary. During her career at Baxter, Ms. Persky managed global legal services, was General Manager of an international medical device business, led international crisis management teams, acquired and integrated international businesses, and designed/implemented legal strategies to manage global mass torts.
In addition to her legal work, Ms. Persky has served on the Board of Directors of Cytyc Corporation, a medical device and diagnostics company dedicated to women’s health. Ms. Persky was a director of Watermark, Inc. a private publisher and broker of children’s literature for over a decade. She is also on the Boards of WESFACCA, Lawyers for Children America, and the Lawyers Collaborative for Diversity.
Ms. Persky practiced with the Chicago firm of Lurie, Sklar & Simon, Ltd. where she specialized in the representation of financial brokers, architects, healthcare organizations and professionals. Before entering the practice of law, Ms. Persky worked in sales and marketing for the Colgate-Palmolive Company.
Ms. Persky has written numerous articles on issues affecting the health care environment published in legal journals, texts and practice guides. She is a recipient of the Illinois State Bar Association Lincoln Memorial Writing Award and received the 2007 Rising Star Award from the Healthcare Businesswomen’s Association. Ms. Persky is a frequent speaker on a variety of subjects including: leadership principles, mentoring, diversity, crisis management, the relationship between attorneys & clients; how product liability laws affect new product development; business practices in a litigious environment; and negotiation techniques.
Ms. Persky received her Juris Doctorate from Washington University School of Law and a Bachelor of Science in Speech Studies from Northwestern University. She lives in Ridgefield, CT with her husband and daughter.
Biogen Idec View Bio »
Barry Ticho, M.D., Ph.D., Vice President, Research and Development. has been with Biogen Idec for over 10 years. He leads Clinical Development for the Tysabri program, which is approved for use in Multiple Sclerosis and is Program Executive for the BART program, which is in development for Alzheimer’s Disease. Barry previously headed the Cardiopulmonary and Emerging Therapeutic Areas, and was involved in in-licensing several pipeline programs. Dr. Ticho obtained his M.D. and Ph.D. degrees from the University of Chicago and completed Pediatric Cardiology training at Children’s Hospital, Boston, MA. He currently maintains a position at Massachusetts General Hospital. Dr. Ticho held a previous position in Clinical Pharmacology at Merck & Co.
Pfizer View Bio »
Pol Vandenbroucke is Vice President, Clinical Development, Emerging Markets Business Unit. Prior to this appointment he was Vice President, Medical and Regulatory Affairs, Canada/Latin America/Africa-Middle East, Vice President, Medical Division Japan, based in Tokyo, and Director of Medical Operations, Asia/Australia/NZ, based in Hong Kong. He moved to Hong Kong from Pfizer HQ in New York where he was a member of the Joint Operating Committee that managed the partnership of Pfizer and Warner-Lambert for Lipitor (atorvastatin), responsible for Pfizer for the international clinical development of Lipitor.
Before joining Pfizer, Pol was US Medical Director, Bayer CC, Medical Director, Sterling-Winthrop International and Cardiovascular Disease Manager at Novartis. His background includes experience in Medical Affairs, Clinical Development and Regulatory experience in the U.S., Europe, Latin America and Asia.
He holds a medical degree and an MBA degree, and is a Member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the UK.
Merck & Co., Inc. View Bio »
Dr. Greg Wiederrecht is the Vice President and Head of External Scientific Affairs (ESA) in the Merck Research Laboratories division of Merck & Co., Inc. where he has been employed for the past 21 years. ESA is responsible for the scientific assessment of all licensing, partnering, and acquisition opportunities for Merck. Dr. Wiederrecht’s responsibilities include the management of a group of 80 scientists and administrators, distributed worldwide and divided by various therapeutic and platform areas, who identify and assess opportunities outside of Merck’s walls.
Dr. Wiederrecht holds a B.S. degree from the University of California, Irvine and a PhD in biochemistry from M.I.T. Before joining Merck in 1989, he was a Helen Hay Whitney Post-Doctoral Fellow and an American Cancer Society Senior Post-Doctoral Fellow at Caltech. Dr. Wiederrecht has published 48 peer reviewed manuscripts and book chapters and has been an invited speaker at more than 50 conferences.
A.T. Kearney View Bio »
Michael Wise is A.T. Kearney’s lead for Sustainability in the Americas, and the lead partner for the Boston office. He has fifteen years of consulting experience, spanning strategic and operational engagements with a focus on healthcare and consumer industries.
Michael has worked with Fortune 500 companies on a broad range of sustainability topics including:
- Developing and embedding a corporate sustainability strategy
- Creating sustainable supply chains
- Determining the potential impact of resource scarcity on an organization’s cost structure
He earned a Masters of Management from Northwestern University’s Kellogg Graduate School of Management, and B.S. in biology from the University of Notre Dame.
Aisling Capital View Bio »
Brett Zbar, M.D. serves as a Partner of Aisling Capital, a leading venture capital and private equity firm that also manages the investments of the Perseus-Soros BioPharmaceutical Fund, LP. Aisling Capital invests in life science companies developing biopharmaceutical products and creates businesses based on advanced life science technologies. Dr. Zbar focuses on investments in development-stage as well as commercial-stage companies, and currently serves as a Director or board observer at Aragon Pharmaceuticals, Catalent Pharma Solutions, and Planet Biopharmaceuticals. Previously, Dr. Zbar was an Associate Principal at McKinsey & Company and a senior member of the Pharmaceuticals and Medical Products practice. While at McKinsey, he worked closely with management of large pharmaceutical companies and specialty pharmaceutical companies based in the U.S., Europe and Japan. Prior to joining McKinsey, Dr. Zbar trained on the Osler internal medicine service at Johns Hopkins Hospital. He received his M.D. from Harvard Medical School and his B.A. from Yale College. Dr. Zbar is a member of the Council on Foreign Relations.
8:00am â€“ 9:00am Breakfast
9:00am â€“ 9:10am Argyle Executive Forum Opening Remarks
9:10am â€“ 9:40am â€śNightmares from the Pillows of General Counselsâ€ť
read more »
Marla S. PerskySenior Vice President, General Counsel and Secretary Boehringer Ingelheim USA CorporationInterviewed By:William HoffmanPartnerKaye Scholer LLP
9:45am â€“ 10:35am Panel Discussion Presented by PwC
read more »
"The Environment for New Drug Developmentâ€ť
- How can we drive more new and innovative drugs in large pharmaceutical companies?
- What impact does consolidation in the industry have on new drug development?
- It seems that the era of 'the blockbuster drug' is waning. Yet the cost to bring a compound to market continues to increase. Can we find less expensive ways to bring drugs to market?
- Do you see private equity firms (including VCs) playing a more prominent role in funding R&D activities in the future?
- What changes are occurring in assessing the economic returns of a potential drug candidate?
- In house discovery vs. in-licensing and strategic alliances â€“ the pros and cons of both methods in identifying new drug candidate
- As developing countries mature, they will require extensive pharmaceutical and healthcare development and investment. Thoughts on opportunities cross border and abroad?
10:40am â€“ 11:00am A.T. Kearney Thought Leadership Spotlight
read more »
"Transforming the Pharma Industry to meet the Challenges of the New Decade"
- Un-precedent challenges are requiring the industry to transform how they do business
- Fundamental changes in the operating model
- Generating value from M&A
andMichael WisePartnerA.T. Kearney
11:00am -11:30am Coffee Break
11:30am â€“ 12:20pm Panel Discussion
read more »
â€śLeadership in Pharmaceuticals & Biotechnologyâ€ť
- The R&D Model- whatâ€™s working, what isnâ€™t and the future of R&D in the life science space The impact of healthcare reform on the pharmaceutical & biotech industry
- What is the role of the pharmaceutical industry in healthcare reform?
- Life cycle management issues: managing early, time to market pressure and the cost/benefit of follow-on drugs.
- Drug portfolio diversification- how can we avoid putting â€śall of our eggs in one basketâ€ť?
12:20pm - 12:25pm Introducing Chris Garabedian:
read more »
Jeff LevyDirector, Business DevelopmentRR Donnelley
12:25pm â€“ 12:55pm "Biotech Business Models"
read more »
Perspectives on valuations, business development strategies, and the role of biotech in pharma's business model.Chris GarabedianPresident & CEO, AVI BioPharma andFormer Vice President, Corporate Strategy, Celgene
12:55pm â€“ 1:55pm Lunch
1:55pm â€“ 2:45pm Panel Discussion
read more »
â€śDeal Making in Pharmaceuticals & Biotechnologyâ€ť
Session Topics include but are not limited to:
- How will economic recovery play a role in pharmaceutical M&A? Why are deal makers expecting things to heat up in 2011? What are the key factors for valuing a deal in todayâ€™s Pharmaceutical & Biotech markets?
- Looking at values from a costs and risks perspective
- Which therapeutic areas pose the best opportunity for deals?
- What deal structure is going to work given the changing regulatory landscape? Drivers behind a particular deal structure
2:45pm - 2:50pm Introducing Greg Wiederrecht, PhD, CLP:
read more »
Linda BowersVP Life Sciences Product MarketingIntraLinks
2:50pm â€“ 3:20pm "Merck's Perspective on Working with External Partners and How it Fits into Our R&D Process"
read more »
Greg Wiederrecht, PhD, CLPVice President & Head, External Scientific Affairs Worldwide Licensing & External ResearchMerck & Co., Inc.*This session is Off the Record
3:25pm â€“ 3:55pm â€śPerrigoâ€™s Perspective on the US Generic Marketâ€ť
read more »
Sharon KochanExecutive Vice President, U.S. GenericsPerrigo Company
3:55pm â€“ 4:00pm Argyle Executive Forum Closing Remarks
4:00pm â€“ 5:00pm Closing Reception
read more »
*Agenda is subject to change
Still have questions? We have answers.
I want to attend, but what if I'm unsure of my schedule and need to cancel my participation?
Just let us know. We understand that schedules
we always have a waiting list for this event,
and if you don't
cancel, we will assume you are still attending
and your spot will
go unused. If you must, cancel at least 48 hours
prior to the
event to make room for others!
What if I can't be OOO for a whole day, or need
to come late?
We have wifi and private rooms available for
attendees to take
calls and spend some quiet time on emails, as
well as access to
printing. Have a morning meeting you can't miss?
No problem. This
event was designed for busy executives - we get
I'd like to bring some colleagues. Do I need to
Events are more fun with friends, and we'd be happy to host your team. You can have them register online, or send us their names, titles and email addresses and we will take care of it for you!
I don't see the event venue listed. Where will
the meeting be
To maintain exclusivity, we don't release the
venue address until
the registration process has been completed. All
details will be shared once you have requested a
pass and been
The 2011 Leadership in Pharmaceuticals & Biotechnology in New York
proudly sponsored by:
Traveling for the event? Stay at one of our
59 West 44th Street
New York, NY 10039
Telephone: (212) 840-6800
49 West 44th Street
New York, NY 10039
Telephone: (212) 977-2719
12 West 44th Street
New York, NY 10039
Telephone: (212) 944-6050
145 West 44th Street
New York, NY 10039
Telephone: (212) 768-4400
44 West 44th Street
New York, NY 10039
Telephone: (212) 869-4400
45 West 44th Street
New York, NY 10039
Telephone: (212) 354-8844